MoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Kristian Reich Sells 1,100 Shares of Stock

Key Points

• Insider sale: Kristian Reich sold 1,100 MoonLake Immunotherapeutics shares for $22,000 at $20 each under a pre-arranged Rule 10b5-1 plan. He still directly owns 2.71 million shares valued at approximately $54.2 million.
• Recent trading and performance: Reich has made several larger sales since June, while MLTX recently traded at $18.36. The stock has a 52-week range of $5.95 to $62.75 and a market capitalization of about $1.35 billion.
• Analyst outlook: Analysts’ consensus rating is “Hold,” with an average price target of $24.21, although several firms maintain Buy or Outperform ratings and targets ranging from $29 to $45.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) insider Kristian Reich sold 1,100 shares of the company's stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $20.00, for a total transaction of $22,000.00. Following the completion of the sale, the insider directly owned 2,711,198 shares in the company, valued at $54,223,960. This trade represents a 0.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kristian Reich also recently made the following trade(s):

• On Tuesday, July 21st, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $20.02, for a total transaction of $1,001,000.00.
• On Monday, July 20th, Kristian Reich sold 43,700 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.09, for a total transaction of $877,933.00.
• On Wednesday, June 17th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $19.43, for a total value of $971,500.00.
• On Monday, June 15th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.89, for a total value of $944,500.00.

MoonLake Immunotherapeutics Price Performance

MLTX stock traded down $0.35 on Wednesday, reaching $18.36. The company had a trading volume of 707,747 shares, compared to its average volume of 1,488,842. The company's fifty day moving average is $19.08 and its 200 day moving average is $17.81. The company has a market cap of $1.35 billion, a P/E ratio of -4.74 and a beta of 1.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.60 and a current ratio of 8.60. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.07). On average, research analysts forecast that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Leerink Partners lifted their price objective on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 1st. BTIG Research reaffirmed a "buy" rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Needham & Company LLC lifted their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, May 12th. HC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of MoonLake Immunotherapeutics in a report on Monday, July 20th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $24.21.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds have recently added to or reduced their stakes in MLTX. Weiss Asset Management LP lifted its holdings in shares of MoonLake Immunotherapeutics by 413.1% during the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company's stock worth $31,843,000 after acquiring an additional 1,375,367 shares during the period. Candriam S.C.A. increased its position in MoonLake Immunotherapeutics by 509.0% during the first quarter. Candriam S.C.A. now owns 818,126 shares of the company's stock worth $15,250,000 after purchasing an additional 683,797 shares during the last quarter. UBS Group AG increased its position in MoonLake Immunotherapeutics by 183.4% during the fourth quarter. UBS Group AG now owns 239,020 shares of the company's stock worth $3,150,000 after purchasing an additional 154,673 shares during the last quarter. GSA Capital Partners LLP purchased a new position in MoonLake Immunotherapeutics during the fourth quarter worth approximately $1,176,000. Finally, Fox Run Management L.L.C. boosted its holdings in shares of MoonLake Immunotherapeutics by 531.2% in the 4th quarter. Fox Run Management L.L.C. now owns 71,962 shares of the company's stock valued at $948,000 after purchasing an additional 60,562 shares during the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.